FairVisitHealth

FairVisitHealth — Aggregated US healthcare price panel at two layers. (1) Procedure/provider layer: 47M+ payer-negotiated rates and 50M+ price data points parsed from hospital price transparency files, payer negotiated-rate files and Medicaid fee schedules, joined to NPI Registry provider listings so rates are attributed to named providers and locations, with each value labelled by evidence type (published cash price vs negotiated-rate evidence vs benchmark estimate). (2) Drug channel layer: a source-linked, weekly-reverified cash-price table for branded GLP-1s (Ozempic, Wegovy, Mounjaro, Zep…

FairVisitHealth offers (Alternative, Price, Reference, Fundamental) — 50M+ price data points and 47M+ payer-negotiated rates across hospital price transparency files, payer negotiated-rate files and Medicaid fee schedules, joined to NPI Registry provider listings across multiple states; the drug layer is a smaller dense panel of branded GLP-1 prices across manufacturer programs, Medicare Part D, telehealth, 503A/503B compounders, discount cards and mail-order pharmacies, each row carrying its own verification date.

Healthcare price-transparency and reference-based-pricing models; self-pay and high-deductible population spending models; benefit design and network narrowing for employers and coalitions; hospital and physician revenue-cycle and price-elasticity work; competitive price benchmarking for payers; GLP-1 franchise price-erosion and channel-shift models as equity-research alpha on branded obesity drugs (the manufacturer-direct vs compounded vs retail spread is a direct read on erosion); and as supervision data, the evidence-class labels plus bill-error and dispute-outcome pairs are usable training sets for healthcare-cost models and document-extraction language models.

The data is with 2 years of history.

Coverage spans US; Health Care Technology, Managed Care; alternative, price, reference, fundamental; equities.